Phase II Study of Adjuvant Radiotherapy After Neoadjuvant Chemotherapy and Immunotherapy in Patients With Locally Advanced Resectable Esophageal Squamous Cell Carcinoma
Led by Zhejiang Cancer Hospital · Updated on 2024-07-16
146
Participants Needed
1
Research Sites
104 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the role of additional radiotherapy after surgery in patients with esophageal squamous cell carcinoma who have a high risk of cancer returning. This study focuses on those who received chemotherapy combined with immunotherapy before surgery but did not have a complete response in the removed tissue. It is a randomized phase II trial comparing outcomes with and without adjuvant radiotherapy to better understand if this extra treatment improves disease control and survival.
Participants are randomly assigned to one of two groups one receives standard treatment including surgery, chemotherapy, immunotherapy, and maintenance immunotherapy for up to one year, while the other group receives the same treatment plus adjuvant radiotherapy starting 4 to 6 weeks after surgery. The radiotherapy is given as intensity-modulated radiation therapy IMRT with a total dose of 45 Gy delivered in 25 sessions over five weeks. After radiotherapy, patients continue immunotherapy maintenance for up to one year or until disease progression. Follow-up visits occur regularly for up to five years.
During the study, participants undergo regular assessments including survival tracking, recurrence monitoring, and quality of life evaluations at various timepoints. Researchers will also study biomarkers such as PD-L1 levels and immune cell activity to predict treatment responses and side effects. Safety is closely monitored during radiotherapy and immunotherapy. The primary goal is to measure disease-free survival at two years, with secondary measures including overall survival and recurrence patterns.
CONDITIONS
Brief Title
Adjuvant Radiotherapy for Esophageal Squamous Cell Carcinoma in the Era of Immunotherapy
Research Team
Y
YANG YANG, M.D.
W
Weizhen Xu
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match. Sign up to get personalized trial recommendations delivered to your inbox.
Resectable or potentially resectable clinical stage cT3-4N0 or T1-4N+ who had 2 cycles of neoadjuvant immunotherapy and chemotherapy followed by R0 surgical resection with postoperative non-complete pathological response
Good organ function including:
Absolute neutrophil count ≥1.5×10⁹/L
Platelet count ≥100×10⁹/L
Hemoglobin ≥90 g/L
Creatinine clearance ≥50 mL/min
Urinary protein less than 2+ or 24-hour urinary protein <1.0 g
Total bilirubin ≤1.5× upper limit normal
AST and ALT ≤2.5× upper limit normal (or ≤5× if liver metastasis)
Serum albumin ≥28 g/L
Coagulation function INR and APTT ≤1.5× upper limit normal (or within expected range if on anticoagulants)
Left ventricular ejection fraction ≥50%
Female subjects of childbearing potential must have negative pregnancy test before first dose and agree to use effective contraception during and 120 days after last dose
Male subjects not surgically sterile with female partners of childbearing potential must use effective contraception during and 120 days after last dose
Willing and able to comply with study visits, treatments, and tests
You will not qualify if you...
Stage IV metastatic esophageal cancer with visceral organ metastasis at diagnosis
Patients who did not achieve R0 resection (R1 or R2 resection)
Patients with complete pathological response after surgery
History of chest radiation therapy
Presence of esophagomediastinal or esophagotracheal fistula before treatment
Pregnant or breastfeeding women
Unable to provide informed consent due to psychological, family, social, or other reasons
History of other malignant tumors except non-melanoma skin cancer, in situ cervical cancer, or cured early prostate cancer
Severe organ dysfunction preventing chemotherapy or radiotherapy
Active or history of autoimmune diseases or immunodeficiency disorders including HIV
Active hepatitis B or C infection above defined levels
History of immunodeficiency or long-term corticosteroid/immunosuppressive use
Severe infection within 4 weeks before treatment or active infection requiring systemic therapy within 2 weeks
Known or suspected active tuberculosis or syphilis
Live vaccination within 30 days before first dose or planned during study
History of interstitial lung disease or non-infectious pneumonitis
History of myocarditis, cardiomyopathy, major arrhythmias, or recent severe cardiac events
Known psychiatric illness, substance abuse, alcoholism, or drug abuse
Other serious local or systemic diseases increasing medical risk or affecting survival assessment
Any condition judged by investigator to pose risk or interfere with study evaluation
Your Study Journey
Screening
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Treatment
Duration - Up to 1 year or until tumor progression
Participants undergo surgery followed by either adjuvant radiotherapy starting 4-6 weeks after surgery or observation with active surveillance. Those receiving radiotherapy get intensity-modulated radiation therapy (IMRT) with 45Gy divided into 25 fractions over 5 weeks. After radiotherapy, participants continue immunotherapy maintenance for up to 1 year or until tumor progression. Participants in the observation group receive maintenance immunotherapy for up to 1 year or until tumor progression.
Radiotherapy: 5 weeks of daily treatments (5 times per week), followed by immunotherapy maintenance every 3 weeks for up to 17 cycles; Observation: immunotherapy maintenance every 3 weeks for up to 17 cycles
Follow-up
Duration - Up to 2 years after surgery
Participants are monitored for disease-free survival, overall survival, recurrence, and quality of life for up to 2 years after surgery.
Visits at 3 months, 1 year, and 2 years after surgery
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Similar Trials
Phase II Study of Adjuvant Radiotherapy After Neoadjuvant Chemotherapy and Immunotherapy in Patients With Locally Advanced Resectable Esophageal Squamous Cell Carcinoma
Comparison of Clinical Outcomes and Molecular Effects of Two Tissue Expanders in Mastectomy Patients Undergoing Breast Reconstruction
Have more questions? Get in touch with our team for quick support
Published Research Related To This Trial
Effect of Camrelizumab vs Placebo Added to Chemotherapy on Survival and Progression-Free Survival in Patients With Advanced or Metastatic Esophageal Squamous Cell Carcinoma: The ESCORT-1st Randomized Clinical Trial.
Distribution of Residual Disease and Recurrence Patterns in Pathological Responders After Neoadjuvant Chemotherapy for Esophageal Squamous Cell Carcinoma.